UNASSIGNED: A systematic search was conducted in the Cochrane Library, PubMed, Web of Science, and Embase for cohort or case-control studies published up to August 2023 on risk factors associated with sepsis-related encephalopathy. The selected studies were screened, data were extracted, and the quality was evaluated using the Newcastle-Ottawa Scale. Meta-analysis was performed using RevMan 5.3 software. The certainty of the evidence was assessed using the GRADE criteria.
UNASSIGNED: A total of 13 studies involving 1,906 participants were included in the analysis. Among these studies, 12 were of high quality, and one was of moderate quality. Our meta-analysis identified six risk factors significantly associated with Serious Adverse Events (SAE). These included APACHE II, SOFA, age, tau protein, and IL-6, which were found to be risk factors with significant effects (standard mean difference SMD: 1.24-2.30), and albumin, which was a risk factor with moderate effects (SMD: -0.55). However, the certainty of evidence for the risk factors identified in this meta-analysis ranged from low to medium.
UNASSIGNED: This systematic review and meta-analysis identified several risk factors with moderate to significant effects. APACHE II, SOFA, age, tau protein, IL-6, and albumin were associated with sepsis-related encephalopathy and were supported by medium- to high-quality evidence. These findings provide healthcare professionals with an evidence-based foundation for managing and treating hospitalized adult patients with sepsis-related encephalopathy.
■在Cochrane图书馆进行了系统搜索,PubMed,WebofScience,和Embase为截至2023年8月发表的关于脓毒症相关性脑病危险因素的队列或病例对照研究。筛选选定的研究,数据被提取,并使用纽卡斯尔-渥太华量表评估质量。采用RevMan5.3软件进行Meta分析。使用等级标准评估证据的确定性。
■共有13项研究纳入分析,涉及1,906名参与者。在这些研究中,12个是高质量的,一个质量适中。我们的荟萃分析确定了与严重不良事件(SAE)显着相关的六个危险因素。其中包括APACHEII,SOFA,年龄,tau蛋白,和IL-6,被发现是具有显着影响的危险因素(标准平均差SMD:1.24-2.30),和白蛋白,这是一个具有中等影响的危险因素(SMD:-0.55)。然而,本荟萃分析中确定的危险因素的证据确定性从低到中不等.
■本系统评价和荟萃分析确定了几个具有中等至显著影响的风险因素。APACHEII,SOFA,年龄,tau蛋白,IL-6和白蛋白与脓毒症相关性脑病相关,并得到中高质量证据的支持。这些发现为医疗保健专业人员提供了基于证据的基础,用于管理和治疗败血症相关脑病的住院成年患者。